No Drip

Description

No Drip Nasal Spray is a formulated dosage form designed for intranasal administration. The product is characterized by its unique formulation that minimizes the occurrence of post-nasal drip. The effective time for this product is noted as October 1, 2022. The media type associated with the product is image/jpeg, and the reference value for the labeling is designated as No drip NasalSpray-Label_page-0001.jpg.

Uses and Indications

This drug is indicated for the temporary relief of nasal congestion associated with the common cold, hay fever, and upper respiratory allergies. It also provides temporary relief from sinus congestion and pressure. Additionally, this drug acts to shrink swollen nasal membranes, facilitating easier breathing.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

To administer the medication, healthcare professionals should instruct patients to hold the white tabs and firmly squeeze the grooved area of the cap while turning it counterclockwise. After use, the cap should be securely replaced to maintain the integrity of the product.

For adults and children aged 6 to under 12 years, the recommended dosage is 2 or 3 sprays in each nostril. This administration should not occur more frequently than every 10 to 12 hours. It is important to ensure that the total number of doses does not exceed 2 in any 24-hour period.

Contraindications

Use is contraindicated in the following situations:

• Use is not recommended for more than 3 days. Prolonged or frequent use may lead to a recurrence or worsening of nasal congestion.

• The product should not be used by more than one person, as this may facilitate the spread of infection.

Warnings and Precautions

Patients should consult a healthcare professional prior to use if they have a history of heart disease, high blood pressure, diabetes, thyroid disease, or difficulty urinating due to an enlarged prostate gland. These conditions may increase the risk of adverse effects and require careful consideration before initiating treatment.

In the event of accidental ingestion, immediate medical assistance should be sought. Patients are advised to contact a Poison Control Center at 1-800-222-1222 or seek emergency medical help without delay.

If symptoms persist despite treatment, patients must discontinue use and consult their healthcare provider for further evaluation and management. Continuous monitoring of symptoms is essential to ensure safe and effective use of the medication.

Side Effects

Patients should be aware of certain warnings prior to using this medication. It is advised to consult a healthcare professional if there is a history of heart disease, high blood pressure, diabetes, thyroid disease, or difficulty urinating due to an enlarged prostate gland.

In pregnant or breastfeeding individuals, it is recommended to seek guidance from a health professional before use to ensure safety for both the mother and child.

In the event that symptoms persist, patients are instructed to discontinue use and consult a doctor for further evaluation and management.

Drug Interactions

There are no specific drug interactions identified in the available data. Additionally, no laboratory test interactions have been reported. Therefore, no dosage adjustments or monitoring recommendations are necessary based on the current information.

Packaging & NDC

Below are the non-prescription pack sizes of No Drip (oxymetazoline hydrochloride). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients aged 6 to under 12 years may receive 2 or 3 sprays in each nostril, administered no more frequently than every 10 to 12 hours. It is important not to exceed 2 doses within a 24-hour period. For children under 6 years of age, consultation with a healthcare professional is advised prior to use.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any adverse effects or changes in therapeutic response, given the lack of targeted data for this population.

Pregnancy

Pregnant patients and those who are breastfeeding should consult a healthcare professional prior to using this medication. The potential risks and benefits must be carefully considered in these populations to ensure the safety of both the mother and the fetus or infant.

Lactation

Lactating mothers are advised to consult a health professional prior to using this medication. There is currently no available data on the excretion of this medication in human breast milk or its effects on breastfed infants. Therefore, caution is recommended when administering this medication to lactating individuals.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available data regarding dosage adjustments, special monitoring, or safety considerations. Therefore, healthcare professionals should exercise caution and consider individual patient factors when prescribing to patients with reduced kidney function, as the absence of specific guidance necessitates careful clinical judgment.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and adhere to general principles of management in cases of suspected overdose.

It is essential to monitor the patient closely for any potential symptoms that may arise, as the clinical presentation can vary depending on the substance involved. Common symptoms of overdose may include, but are not limited to, respiratory depression, altered mental status, cardiovascular instability, and gastrointestinal disturbances.

In the event of an overdose, immediate medical attention should be sought. Healthcare providers should initiate supportive care, which may include maintaining airway patency, providing supplemental oxygen, and monitoring vital signs. The use of activated charcoal may be considered if the patient presents within a suitable timeframe and if the ingestion was recent.

Furthermore, specific antidotes or treatments may be indicated based on the clinical scenario and the substance involved. Consultation with a poison control center or a medical toxicologist is recommended for guidance on the appropriate management strategies tailored to the individual case.

Overall, vigilance and prompt intervention are critical in managing potential overdosage situations effectively.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the compound in these areas.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to keep the medication out of reach of children. Instruct patients that if the medication is swallowed, they should seek medical help or contact a Poison Control Center immediately at 1-800-222-1222.

Patients should be informed to stop using the medication and consult a doctor if their symptoms persist. It is important to emphasize that they should not exceed the recommended dosage and should not use the medication for more than three days. Frequent or prolonged use may lead to a recurrence or worsening of nasal congestion.

Patients may experience temporary discomfort, which can include burning, stinging, sneezing, or an increase in nasal discharge. Additionally, healthcare providers should caution patients that the use of this container by more than one person may increase the risk of spreading infection.

Storage and Handling

The product is supplied in a carton that should be retained for future reference on full labeling. It is essential to store the product within a temperature range of 68° F (20° C) to 86° F (30° C) to ensure its stability and efficacy. Proper storage conditions must be maintained to preserve the integrity of the product.

Additional Clinical Information

The route of administration for the medication is nasal. Clinicians should advise patients who are pregnant or breastfeeding to consult a health professional prior to use. Additionally, it is important to inform patients that using this container by more than one person may lead to the spread of infection.

Drug Information (PDF)

This file contains official product information for No Drip, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)